Amgen stock (US0311621009): $300M Puerto Rico investment signals manufacturing expansion

Amgen announced a $300 million investment in its Puerto Rico biologics facility in early May 2026, expanding production capacity and workforce development as the biotech giant pursues next-generation manufacturing capabilities.

Amgen announced a $300 million investment in its large biologics manufacturing facility in Juncos, Puerto Rico in early May 2026, according to SimplyWall.st as of May 11, 2026. The expansion targets next-generation production capacity, workforce development, and supply chain reliability for the company's biologics portfolio.

As of: May 11, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biopharmaceuticals and biologics manufacturing
• Headquarters/country: United States
• Core markets: Global pharmaceutical and biologics markets
• Key revenue drivers: Biologics, oncology, cardiovascular, and inflammation therapies
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen: core business model

Amgen is one of the world's largest independent biopharmaceutical companies, specializing in the discovery, development, manufacturing, and delivery of human therapeutics. The company operates across multiple therapeutic areas including oncology, cardiovascular disease, inflammation, and bone health. Amgen's business model centers on proprietary biologics—large-molecule drugs produced through biotechnology—which command premium pricing and generate substantial recurring revenue streams from chronic disease management.

Manufacturing expansion and supply chain strategy

The $300 million Puerto Rico investment reflects Amgen's strategic focus on securing and expanding manufacturing capacity for its biologics pipeline. The Juncos facility, already a significant production hub, will benefit from capital deployment aimed at modernizing equipment, increasing throughput, and training a larger workforce. This move addresses industry-wide supply chain pressures and positions Amgen to meet growing global demand for its existing and pipeline biologics therapies.

Recent financial and operational context

Amgen reported revenue growth of 5.8% in its most recent quarter compared to the same period last year, according to MarketBeat as of May 11, 2026. The company maintained a net profit margin of 20.96% and achieved a return on equity of 137.41%, demonstrating strong operational efficiency and shareholder value generation. The stock traded at $331.70 USD on Nasdaq as of May 11, 2026, with a market capitalization of approximately $179 billion.

Pipeline developments and competitive positioning

Amgen continues to advance its cardiovascular and metabolic disease portfolio. In March 2026, the company presented Phase 3 data from its Vesalius-CV trial showing that its PCSK9 inhibitor candidate significantly reduced the risk of first cardiovascular events in high-risk primary prevention patients, a first-in-class achievement for this drug category. The company is also developing olpasiran, a small interfering RNA therapy targeting lipoprotein(a), with outcome trial results expected in 2027.

Conclusion

Amgen's $300 million Puerto Rico investment underscores the company's commitment to manufacturing excellence and supply chain resilience in an increasingly competitive biologics market. Combined with recent pipeline progress in cardiovascular disease and strong financial performance, the expansion signals management confidence in sustained demand for its therapeutic portfolio. US investors tracking large-cap biopharmaceutical exposure should monitor execution on this capital deployment and upcoming clinical trial readouts in 2027.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.